$3.98 Billion is the total value of BB BIOTECH AG's 35 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 8.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IONS | Sell | Ionis Pharmaceuticals Inc. | $627,038,000 | +32.7% | 7,725,000 | -11.6% | 15.76% | +4.1% |
| INCY | Sell | Incyte Corp. | $311,356,000 | +28.6% | 3,620,000 | -4.9% | 7.83% | +0.9% |
| NBIX | Buy | Neurocrine Biosciences Inc. | $296,614,000 | +24.2% | 3,366,786 | +0.7% | 7.46% | -2.5% |
| VRTX | Sell | Vertex Pharmaceuticals Inc | $239,135,000 | +5.3% | 1,300,000 | -5.1% | 6.01% | -17.4% |
| SAGE | Sage Therapeutics, Inc. | $218,730,000 | +66.0% | 1,375,229 | 0.0% | 5.50% | +30.3% | |
| CELG | Sell | Celgene Corp | $207,548,000 | +40.6% | 2,200,000 | -4.5% | 5.22% | +10.3% |
| AGIO | Buy | Agios Pharmaceuticals, Inc. | $200,845,000 | +51.3% | 2,978,134 | +3.5% | 5.05% | +18.7% |
| ALXN | Alexion Pharmaceuticals, Inc. | $177,684,000 | +38.8% | 1,314,428 | 0.0% | 4.47% | +9.0% | |
| ALNY | Buy | Alnylam Pharmaceuticals, Inc. | $152,425,000 | +33.0% | 1,631,089 | +3.8% | 3.83% | +4.4% |
| ESPR | Buy | Esperion Therapeutics, Inc. | $141,447,000 | -9.4% | 3,522,964 | +3.8% | 3.56% | -28.9% |
| RDUS | Buy | Radius Health, Inc. | $135,227,000 | +22.2% | 6,781,685 | +1.1% | 3.40% | -4.1% |
| HALO | Halozyme Therapeutics Inc. | $133,998,000 | +10.0% | 8,322,860 | 0.0% | 3.37% | -13.6% | |
| ARGX | Buy | Argenx SEsponsored adr | $112,948,000 | +32.9% | 904,739 | +2.3% | 2.84% | +4.3% |
| MRNA | Moderna, Inc. | $97,389,000 | +33.3% | 4,785,681 | 0.0% | 2.45% | +4.6% | |
| MYOV | Myovant Sciences Ltd. | $85,881,000 | +45.5% | 3,597,882 | 0.0% | 2.16% | +14.2% | |
| ICPT | Buy | Intercept Pharmaceuticals, Inc. | $77,964,000 | +34.4% | 696,976 | +21.1% | 1.96% | +5.4% |
| GILD | Sell | Gilead Sciences Inc. | $74,255,000 | -10.9% | 1,142,204 | -14.3% | 1.87% | -30.1% |
| NKTR | Buy | Nektar Therapeutics | $67,895,000 | +49.6% | 2,020,676 | +46.3% | 1.71% | +17.4% |
| EXEL | Exelixis, Inc. | $67,473,000 | +21.0% | 2,835,000 | 0.0% | 1.70% | -5.1% | |
| AKCA | Sell | Akcea Therapeutics, Inc. | $67,358,000 | -6.4% | 2,377,638 | -0.4% | 1.69% | -26.5% |
| MYOK | Buy | Myokardia Inc. | $65,763,000 | +53.4% | 1,264,913 | +44.2% | 1.65% | +20.4% |
| MGNX | Buy | MacroGenics Inc. | $61,132,000 | +46.6% | 3,400,000 | +3.6% | 1.54% | +15.0% |
| WVE | Wave Life Sciences Ltd. | $56,915,000 | -7.6% | 1,465,002 | 0.0% | 1.43% | -27.5% | |
| VYGR | Voyager Therapeutics, Inc. | $54,852,000 | +103.6% | 2,865,841 | 0.0% | 1.38% | +59.8% | |
| BOLD | Buy | Audentes Therapeutics, Inc. | $53,442,000 | +225.8% | 1,369,604 | +78.0% | 1.34% | +155.3% |
| ALDR | Alder Biopharmaceuticals Inc. | $37,756,000 | +33.2% | 2,766,008 | 0.0% | 0.95% | +4.5% | |
| CRSP | New | Crispr Therapeutics AGnamen akt | $28,950,000 | – | 810,462 | +100.0% | 0.73% | – |
| SRRK | Buy | Scholar Rock Holding Corp | $27,750,000 | -5.6% | 1,476,839 | +15.4% | 0.70% | -25.9% |
| ITCI | Intra-Cellular Therapies, Inc. | $26,796,000 | +6.9% | 2,200,000 | 0.0% | 0.67% | -16.1% | |
| SGMO | Buy | Sangamo Therapeutics, Inc | $25,281,000 | +63.1% | 2,650,000 | +96.3% | 0.64% | +28.0% |
| KZR | Buy | Kezar Life Sciences, Inc. | $21,652,000 | +12.1% | 1,220,503 | +49.1% | 0.54% | -12.1% |
| GTHX | G1 Therapeutics, Inc. | $11,154,000 | -13.3% | 671,925 | 0.0% | 0.28% | -32.0% | |
| CDTX | Cidara Therapeutics, Inc. | $6,082,000 | +12.8% | 2,295,272 | 0.0% | 0.15% | -11.6% | |
| NVAX | Novavax Inc. | $4,589,000 | -70.1% | 8,330,000 | 0.0% | 0.12% | -76.6% | |
| FIXX | New | Homology Medicines, Inc. | $2,533,000 | – | 91,336 | +100.0% | 0.06% | – |
| REGN | Exit | Regeneron Pharmaceuticals Inc. | $0 | – | -68,156 | -100.0% | -0.82% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N V #1
- Biotech Invest N V #2
- Biotech Target N V #3
- Biotech Growth N V #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.